3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
7
CNS
1
Conditions
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Neoplasms
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Interventions
Temozolomide
123
Radiotherapy
47
Bevacizumab
46
Lomustine
25
Radiation
20
Nivolumab
17
Irinotecan
16
Carboplatin
16
Cyclophosphamide
14
Granulocyte-Macrophage Colony-Stimulating Factor
13
pembrolizumab
11
dabrafenib
10
Trastuzumab
10
Surgical Procedures, Operative
10
Capecitabine
10
paclitaxel-Angiopep-2 conjugate
8
TIC10 compound
8
Paclitaxel
8
Gemcitabine
8
Carmustine
8
trametinib
7
Topotecan
7
IL13-PE38
7
Everolimus
7
Drug Therapy
7
Aminolevulinic Acid
7
AZD 6244
7
3-Iodobenzylguanidine
7
fludarabine
6
enzastaurin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
RAD1901
×
CNS
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled